Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems

Details for Australian Patent Application No. 2006227816 (hide)

Owner Allergan, Inc.

Inventors Aoki, Kei R.; Gilmore, Marcella A.; Fernandez-Salas, Ester; Francis, Joseph; Li, Shengwen; Steward, Lance E.

Agent Davies Collison Cave

Pub. Number AU-B-2006227816

PCT Pub. Number WO2006/101809

Priority 60/661,953 15.03.05 US; 60/662,151 15.03.05 US

Filing date 14 March 2006

Wipo publication date 28 September 2006

Acceptance publication date 5 April 2012

International Classifications

C07K 14/33 (2006.01) Peptides having more than 20 amino acids

A61K 38/16 (2006.01) Medicinal preparations containing peptides - Peptides having more than 20 amino acids

C07K 14/50 (2006.01) Peptides having more than 20 amino acids

Event Publications

11 October 2007 PCT application entered the National Phase

  PCT publication WO2006/101809 Priority application(s): WO2006/101809

5 April 2012 Application Accepted

  Published as AU-B-2006227816

2 August 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006227828-Feminine product disposal container

2006227815-Pyrrolidine derivatives as histamine H3 receptor antagonists